gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

A prospective multicentre evaluation of intensive treatment including high dose chemotherapy (HDT) and PSCR for Ewing’s tumours (ET) with extra-pulmonary metastatic disease (EPMD). Results on behalf ofthe Euro-Ewing 99 Study Group

Meeting Abstract

  • corresponding author presenting/speaker Ruth Ladenstein - St. Anna Kinderspital, Wien, Österreich
  • Jeremy Whelan - Middlesex Hospital, London
  • Odile Oberlin - Institut Gustave Roussy, Villejuif
  • Claire Weston - UKCCSG Data Centre, Leicester
  • Herbert Jürgens - Univ.Klinik für Kinderheilkunde, Münster

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO409

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 20. März 2006

© 2006 Ladenstein et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Purpose: Development of an effective strategy for patients with EPMD.

Patients and Methods: Of 192 patients (pts) registered, 141pts have completed treatment. Median age is 15.8 years (yrs) ( 0.4-49.29). Primary site was extremity in 57pts and axial/other in 135pts (40.6% in the pelvis). Tumour volume was ≥200ml in 114pts. Metastatic spread was bone marrow (BM) only in 17pts, bone only in 94pts and bone&BM in 79pts. Other metastatic sites involved in addition lung (81pts), liver (7pts), CNS (7pts) and lymph nodes (11pts). Six VIDE induction cycles were completed by 123pts; reasons for <6VIDE were toxicity(7), patient choice(2 ), progression(6). Local treatment (surgery when possible and/or radiotherapy (Rx) as indicated) was documented in 86pts. Recommended HDT was busulphan 600mg/m² and melphalan 140 mg/m² with PSCR. Median follow up is 2 years (range 0.0-4.6).

Results: Partial remission or better was achieved in 45 by cycle 6 (42%). The overall survival at 2 years for all 192 pts is 32.8 (95% CI: 24.3– 41.3). Of 141pts only 84 pts received BuMel-HDT and 10 pts other HDT. BuMel pts achieved an OS of 30% at 2 years. Significantly favourable OS factors at Dx are age < 14 yrs (p=0.0069), BM involvement only (p=0.0057), single bone lesions only (p=0.0043), tumour volume of <200ml (p=0.0004).

Conclusions: Further strategy refinement and validation of HDT appears necessary within investigational, ideally randomised studies.